Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man
Interventions
BIOLOGICAL

VSL#3

"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."

BIOLOGICAL

Placebo

Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.

Trial Locations (1)

SE41345

Dept of Gastrosurgical R&E, Sahlgrenska Universityhospital, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

lead

Göteborg University

OTHER

NCT01635192 - Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System | Biotech Hunter | Biotech Hunter